Biosimilar trends in 2016

Spurring the growth of biosimilars is the need to improve access to biologics and contain treatment costs and healthcare budgets,…

US FDA approves ipilimumab

Ipilimumab improved adjuvant treatment of patients with cutaneous melanoma The US Food and Drug Administration (FDA) has approved ipilimumab (Yervoy…